For a better experience, Read this story in our App
+ 677.55
+ 227.90
-123.00
-1,081.00
+ 57.00
+ 677.55
+ 227.90
+ 227.90
-123.00
-123.00
-1,081.00
Glenmark Therapeutics Inc., USA announced today the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent (OTC), a generic version of Pataday® Twice Daily Relief.
The over-the-counter eye drop solution enters a market that achieved annual sales of $26.4 million for the 52-week period ending July 13, 2024, according to Nielsen® data.
The shares of Glenmark Therapeutics Inc. were trading at ₹1,606.00 up by 40.20 or (2.57 per cent) on NSE at 10 am on Monday.
Fabio Moreno, Head of OTC Sales & Marketing at Glenmark Pharmaceuticals Inc., stated, “We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1 per cent, addressing the growing demand for a new supplier in this category.
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers.”
Published on August 19, 2024
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.